List of Tables
Table 1: Ophthalmology Disease Therapeutics Market, Symptoms of Glaucoma, AMD, DME, DR and DES 12
Table 2: Ophthalmology Disease Therapeutics Market, Etiology of Glaucoma, AMD, DME, DR and DES 14
Table 3: Ophthalmology Disease Therapeutics Market, Complications associated with glaucoma, AMD, DR and DES 19
Table 4: Ophthalmology, Global, Epidemiology of Ophthalmologic Disorders, 2017 21
Table 5: Ophthalmology Disease Therapeutics Market, Treatment options available for glaucoma 27
Table 6: Ophthalmology Therapeutics Market, Global, Approved Indications for Lucentis, 2017 29
Table 7: Ophthalmology Therapeutics Market, Global, Approved Indications for Eylea, 2017 31
Table 8: Ophthalmology Therapeutics Market, Global, Off-label Indications for Avastin, 2016 32
Table 9: Ophthalmology Therapeutics Market, Global, Approved Indications for Restasis, 2017 34
Table 10: Ophthalmology Therapeutics Market, Global, Approved Indications for Alphagan, 2017 35
Table 11: Ophthalmology Therapeutics Market, Global, Approved Indications for Lumigan, 2017 36
Table 12: Ophthalmology Therapeutics Market, Global, Approved Indications for Xalatan, 2017 37
Table 13: Opthallmology, Global, Annual Revenue Forecast for Key Products ($bn), 2016-2023 66
Table 14: Ophthalmology Therapeutics Market, Global, Forecast Revenues by Company, 2016–2023 75
Table 15: Ophthalmology Therapeutics Market, Global, Licensing Deals Valued Above $100m, 2006–2017 100
Table 16: Ophthalmology Therapeutics Market, Global, Co-development Deals Valued Above $100m, 2006–2017 110